AlloHSC-iNKT cells express reduced levels of HLA-I molecules and nearly undetectable levels of HLA-II molecules, which seems to be genomically programmed (Figure 2I) and stable through the in vitro culture and in vivo persistence even within the tumor microenvironment (Figures 6A–6F); this feature may allow these cells to resist allorejection by host T cells and thereby alleviate the need for additional HLA gene editing or intense host T cell depletion preconditioning treatment (e.g., CD52 antibody treatment).10 Here, CD52 is linked to neoplasm.